Aleksandra Franczak, Paul Calistrate-Petre, Irina Dinu, Paul Jurasz
{"title":"The association of angiostatin and plasminogen plasma levels with Charlson comorbidity burden and mortality in COVID-19.","authors":"Aleksandra Franczak, Paul Calistrate-Petre, Irina Dinu, Paul Jurasz","doi":"10.1007/s11239-026-03289-1","DOIUrl":null,"url":null,"abstract":"<p><p>Severe COVID-19 is associated with thrombotic complications. Dysregulated fibrinolysis, marked by increased plasminogen activator inhibitor-1 (PAI-1) and reduced plasmin generation, has been linked to adverse outcomes including death. Plasmin(ogen) is also the precursor of angiostatin, an angiogenesis inhibitor with dual roles both preventing SARS-CoV-2 infection and promoting cell death. While alterations in fibrinolytic markers are associated with disease severity, the relationship between plasminogen and angiostatin with survival outcomes remains unclear. Therefore we compared plasma angiostatin and plasminogen levels between COVID-19 survivors and non-survivors and assessed their association with mortality. The observational cohort study included age- and sex-matched hospitalized COVID-19 survivors and non-survivors. Plasma samples were collected during hospitalization, and angiostatin and plasminogen levels were quantified by immunoblotting. Cox regression, adjusted for Charlson comorbidity score and time from symptom onset to sample collection, assessed their association with mortality. Non-survivors had a higher Charlson score and significantly lower plasma angiostatin and plasminogen levels compared to survivors. Angiostatin was not associated with mortality after multivariate analysis. However, exploratory Kaplan-Meier survival curve analysis suggested that individuals with lowest Charlson score and angiostatin within the lower tertile exhibit lowest survival probability, while individuals with high Charlson score and with angiostatin in the middle tertile exhibit longest survival probability. By contrast, lower plasminogen was independently associated with mortality after adjustments, supporting a role for impaired fibrinolysis in poor outcomes, while a more complex potential association between angiostatin and COVID-19 mortality is emerging consistent with its dual roles in SARS-CoV-2 infection.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":"1591-1599"},"PeriodicalIF":2.1000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thrombosis and Thrombolysis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11239-026-03289-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Severe COVID-19 is associated with thrombotic complications. Dysregulated fibrinolysis, marked by increased plasminogen activator inhibitor-1 (PAI-1) and reduced plasmin generation, has been linked to adverse outcomes including death. Plasmin(ogen) is also the precursor of angiostatin, an angiogenesis inhibitor with dual roles both preventing SARS-CoV-2 infection and promoting cell death. While alterations in fibrinolytic markers are associated with disease severity, the relationship between plasminogen and angiostatin with survival outcomes remains unclear. Therefore we compared plasma angiostatin and plasminogen levels between COVID-19 survivors and non-survivors and assessed their association with mortality. The observational cohort study included age- and sex-matched hospitalized COVID-19 survivors and non-survivors. Plasma samples were collected during hospitalization, and angiostatin and plasminogen levels were quantified by immunoblotting. Cox regression, adjusted for Charlson comorbidity score and time from symptom onset to sample collection, assessed their association with mortality. Non-survivors had a higher Charlson score and significantly lower plasma angiostatin and plasminogen levels compared to survivors. Angiostatin was not associated with mortality after multivariate analysis. However, exploratory Kaplan-Meier survival curve analysis suggested that individuals with lowest Charlson score and angiostatin within the lower tertile exhibit lowest survival probability, while individuals with high Charlson score and with angiostatin in the middle tertile exhibit longest survival probability. By contrast, lower plasminogen was independently associated with mortality after adjustments, supporting a role for impaired fibrinolysis in poor outcomes, while a more complex potential association between angiostatin and COVID-19 mortality is emerging consistent with its dual roles in SARS-CoV-2 infection.
期刊介绍:
The Journal of Thrombosis and Thrombolysis is a long-awaited resource for contemporary cardiologists, hematologists, vascular medicine specialists and clinician-scientists actively involved in treatment decisions and clinical investigation of thrombotic disorders involving the cardiovascular and cerebrovascular systems. The principal focus of the Journal centers on the pathobiology of thrombosis and vascular disorders and the use of anticoagulants, platelet antagonists, cell-based therapies and interventions in scientific investigation, clinical-translational research and patient care.
The Journal will publish original work which emphasizes the interface between fundamental scientific principles and clinical investigation, stimulating an interdisciplinary and scholarly dialogue in thrombosis and vascular science. Published works will also define platforms for translational research, drug development, clinical trials and patient-directed applications. The Journal of Thrombosis and Thrombolysis'' integrated format will expand the reader''s knowledge base and provide important insights for both the investigation and direct clinical application of the most rapidly growing fields in medicine-thrombosis and vascular science.